Compare · NVCT vs PFE
NVCT vs PFE
Side-by-side comparison of Nuvectis Pharma Inc. (NVCT) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVCT and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE carries a market cap of $304.95B.
- PFE has hit the wire 10 times in the past 4 weeks while NVCT has been quiet.
- PFE has more recent analyst coverage (25 ratings vs 4 for NVCT).
- Company
- Nuvectis Pharma Inc.
- Pfizer Inc.
- Price
- $8.89+2.48%
- $26.98+1.20%
- Market cap
- -
- $304.95B
- 1M return
- +11.40%
- -
- 1Y return
- -17.02%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 10
- Recent ratings
- 4
- 25
Nuvectis Pharma Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest NVCT
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
- SEC Form EFFECT filed by Nuvectis Pharma Inc.
- SEC Form S-3 filed by Nuvectis Pharma Inc.
- Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Nuvectis Pharma Inc.
- Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
- Chief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 9% to 1,793,068 units (SEC Form 4)
- Chairman & CEO Bentsur Ron was granted 150,000 shares, increasing direct ownership by 4% to 3,675,924 units (SEC Form 4)
- Chief Science & Business Off Poradosu Enrique was granted 150,000 shares, increasing direct ownership by 9% to 1,806,319 units (SEC Form 4)
- Vice President, Finance Carson Michael J. was granted 61,200 shares, increasing direct ownership by 44% to 200,118 units (SEC Form 4)
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities